Barriers to drug discovery and development for Alzheimer disease

Howard M. Fillit, Alan W. O'Connell, William M. Brown, Larry D. Altstiel, Ravi Anand, Katherine Collins, Steven H. Ferris, Zaven S. Khachaturian, June Kinoshita, Linda Van Eldik, C. Forbes Dewey

Research output: Contribution to journalArticle

Abstract

Alzheimer disease (AD) is a neurodegenerative condition leading to progressive, irreversible loss of cognitive and behavioral function. Despite considerable investments in neuroscience research, only four drugs, all cholinesterase inhibitors, have been approved for the symptomatic management of AD in the United States. Although basically safe and modestly effective, these drugs are far from ideal, being neither universally efficacious nor disease modifying. AD exacts a considerable toll in direct medical costs, quality of life, and caregiver burden for persons and society. In addition to the obvious clinical benefit, therapeutic agents for AD and related dementias represent a considerable market opportunity for the pharmaceutical and biotechnology industries. There are currently 8-10 million AD sufferers in the seven major pharmaceutical markets. The market will grow rapidly in coming decades, as the developed world experiences an enormous increase in its elderly population. Given the great need for new therapeutic agents to manage and prevent AD, the Institute for the Study of Aging and the Fidelity Foundation organized a workshop, "Barriers to the Discovery and Development of Drugs for Alzheimer's Disease," to examine ways to expedite drug discovery and development. The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail.

Original languageEnglish (US)
JournalAlzheimer Disease and Associated Disorders
Volume16
Issue numberSUPPL. 1
StatePublished - 2002
Externally publishedYes

Fingerprint

Drug Discovery
Alzheimer Disease
Pharmaceutical Preparations
Cholinesterase Inhibitors
Drug Industry
Biotechnology
Neurosciences
Cognition
Caregivers
Dementia
Quality of Life
Education
Costs and Cost Analysis
Therapeutics
Research
Population

Keywords

  • Aging
  • Alzheimer disease
  • Dementia
  • Drug development
  • Drug discovery

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Fillit, H. M., O'Connell, A. W., Brown, W. M., Altstiel, L. D., Anand, R., Collins, K., ... Dewey, C. F. (2002). Barriers to drug discovery and development for Alzheimer disease. Alzheimer Disease and Associated Disorders, 16(SUPPL. 1).

Barriers to drug discovery and development for Alzheimer disease. / Fillit, Howard M.; O'Connell, Alan W.; Brown, William M.; Altstiel, Larry D.; Anand, Ravi; Collins, Katherine; Ferris, Steven H.; Khachaturian, Zaven S.; Kinoshita, June; Van Eldik, Linda; Dewey, C. Forbes.

In: Alzheimer Disease and Associated Disorders, Vol. 16, No. SUPPL. 1, 2002.

Research output: Contribution to journalArticle

Fillit, HM, O'Connell, AW, Brown, WM, Altstiel, LD, Anand, R, Collins, K, Ferris, SH, Khachaturian, ZS, Kinoshita, J, Van Eldik, L & Dewey, CF 2002, 'Barriers to drug discovery and development for Alzheimer disease', Alzheimer Disease and Associated Disorders, vol. 16, no. SUPPL. 1.
Fillit HM, O'Connell AW, Brown WM, Altstiel LD, Anand R, Collins K et al. Barriers to drug discovery and development for Alzheimer disease. Alzheimer Disease and Associated Disorders. 2002;16(SUPPL. 1).
Fillit, Howard M. ; O'Connell, Alan W. ; Brown, William M. ; Altstiel, Larry D. ; Anand, Ravi ; Collins, Katherine ; Ferris, Steven H. ; Khachaturian, Zaven S. ; Kinoshita, June ; Van Eldik, Linda ; Dewey, C. Forbes. / Barriers to drug discovery and development for Alzheimer disease. In: Alzheimer Disease and Associated Disorders. 2002 ; Vol. 16, No. SUPPL. 1.
@article{ba70bbbffb81480f94b0aa15b1321ff7,
title = "Barriers to drug discovery and development for Alzheimer disease",
abstract = "Alzheimer disease (AD) is a neurodegenerative condition leading to progressive, irreversible loss of cognitive and behavioral function. Despite considerable investments in neuroscience research, only four drugs, all cholinesterase inhibitors, have been approved for the symptomatic management of AD in the United States. Although basically safe and modestly effective, these drugs are far from ideal, being neither universally efficacious nor disease modifying. AD exacts a considerable toll in direct medical costs, quality of life, and caregiver burden for persons and society. In addition to the obvious clinical benefit, therapeutic agents for AD and related dementias represent a considerable market opportunity for the pharmaceutical and biotechnology industries. There are currently 8-10 million AD sufferers in the seven major pharmaceutical markets. The market will grow rapidly in coming decades, as the developed world experiences an enormous increase in its elderly population. Given the great need for new therapeutic agents to manage and prevent AD, the Institute for the Study of Aging and the Fidelity Foundation organized a workshop, {"}Barriers to the Discovery and Development of Drugs for Alzheimer's Disease,{"} to examine ways to expedite drug discovery and development. The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail.",
keywords = "Aging, Alzheimer disease, Dementia, Drug development, Drug discovery",
author = "Fillit, {Howard M.} and O'Connell, {Alan W.} and Brown, {William M.} and Altstiel, {Larry D.} and Ravi Anand and Katherine Collins and Ferris, {Steven H.} and Khachaturian, {Zaven S.} and June Kinoshita and {Van Eldik}, Linda and Dewey, {C. Forbes}",
year = "2002",
language = "English (US)",
volume = "16",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Barriers to drug discovery and development for Alzheimer disease

AU - Fillit, Howard M.

AU - O'Connell, Alan W.

AU - Brown, William M.

AU - Altstiel, Larry D.

AU - Anand, Ravi

AU - Collins, Katherine

AU - Ferris, Steven H.

AU - Khachaturian, Zaven S.

AU - Kinoshita, June

AU - Van Eldik, Linda

AU - Dewey, C. Forbes

PY - 2002

Y1 - 2002

N2 - Alzheimer disease (AD) is a neurodegenerative condition leading to progressive, irreversible loss of cognitive and behavioral function. Despite considerable investments in neuroscience research, only four drugs, all cholinesterase inhibitors, have been approved for the symptomatic management of AD in the United States. Although basically safe and modestly effective, these drugs are far from ideal, being neither universally efficacious nor disease modifying. AD exacts a considerable toll in direct medical costs, quality of life, and caregiver burden for persons and society. In addition to the obvious clinical benefit, therapeutic agents for AD and related dementias represent a considerable market opportunity for the pharmaceutical and biotechnology industries. There are currently 8-10 million AD sufferers in the seven major pharmaceutical markets. The market will grow rapidly in coming decades, as the developed world experiences an enormous increase in its elderly population. Given the great need for new therapeutic agents to manage and prevent AD, the Institute for the Study of Aging and the Fidelity Foundation organized a workshop, "Barriers to the Discovery and Development of Drugs for Alzheimer's Disease," to examine ways to expedite drug discovery and development. The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail.

AB - Alzheimer disease (AD) is a neurodegenerative condition leading to progressive, irreversible loss of cognitive and behavioral function. Despite considerable investments in neuroscience research, only four drugs, all cholinesterase inhibitors, have been approved for the symptomatic management of AD in the United States. Although basically safe and modestly effective, these drugs are far from ideal, being neither universally efficacious nor disease modifying. AD exacts a considerable toll in direct medical costs, quality of life, and caregiver burden for persons and society. In addition to the obvious clinical benefit, therapeutic agents for AD and related dementias represent a considerable market opportunity for the pharmaceutical and biotechnology industries. There are currently 8-10 million AD sufferers in the seven major pharmaceutical markets. The market will grow rapidly in coming decades, as the developed world experiences an enormous increase in its elderly population. Given the great need for new therapeutic agents to manage and prevent AD, the Institute for the Study of Aging and the Fidelity Foundation organized a workshop, "Barriers to the Discovery and Development of Drugs for Alzheimer's Disease," to examine ways to expedite drug discovery and development. The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail.

KW - Aging

KW - Alzheimer disease

KW - Dementia

KW - Drug development

KW - Drug discovery

UR - http://www.scopus.com/inward/record.url?scp=0036285724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036285724&partnerID=8YFLogxK

M3 - Article

C2 - 12070355

AN - SCOPUS:0036285724

VL - 16

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - SUPPL. 1

ER -